



Contents lists available at ScienceDirect

## Diabetes &amp; Metabolic Syndrome: Clinical Research &amp; Reviews

journal homepage: [www.elsevier.com/locate/dsx](http://www.elsevier.com/locate/dsx)

## Insulin-induced skin lipohypertrophies: A neglected cause of hypoglycemia in dialysed individuals with diabetes



Sandro Gentile <sup>a, c</sup>, Ersilia Satta <sup>a, d</sup>, Felice Strollo <sup>a, b</sup>, Giuseppina Guarino <sup>c</sup>, Carmine Romano <sup>a</sup>, Teresa Della Corte <sup>a, c, \*</sup>, Carmelo Alfarone <sup>a</sup>, on behalf of Study Group AMD-OSDI on Injection Technique, and Nefrocenter Research & Nyx Start-up<sup>1</sup>

<sup>a</sup> Nefrocenter Research Network & Nyx Innovative Research Start-Up, Naples, Italy

<sup>b</sup> Endocrinology and Diabetes, San Raffaele Termini Institute, Rome, Italy

<sup>c</sup> Department of Internal Medicine, Campania University "Luigi Vanvitelli", Naples, Italy

<sup>d</sup> Multi-specialty Nephrology Center (CNP) Srl, Frattamaggiore, Italy

### ARTICLE INFO

#### Article history:

Received 6 May 2020

Received in revised form

11 May 2021

Accepted 12 May 2021

#### Keywords:

Diabetes

Lipohypertrophy

Injection technique

Hypoglycemia

Diabetic nephropathy

### ABSTRACT

**Background:** Diabetes mellitus (DM) is the leading cause of end-stage renal disease and 50% of dialysis patients are insulin-treated.

**Aim:** to search for unexplained hypoglycemia (HYPO).

**Methods:** identify a possible cause of HYPO due to altered insulin absorption.

**Results:** insulin injected into subcutaneous lipo-hypertrophy (LH) nodules leads to unpredictable HYPOS.

**Conclusion:** looking for LH systematically and training patients to the best injection technique are new challenges for nephrologists to reduce HYPO and emergency hospitalization rates, thus sparing healthcare resources and improving the quality of life of insulin-treated dialysis patients.

© 2021 Diabetes India. Published by Elsevier Ltd. All rights reserved.

The incidence and prevalence of type 2 diabetes mellitus (T2DM) have grown all over the world for the last ten years or so, thus causing a marked increase in the number of people developing diabetic kidney disease (DKD) [1].

Apropos of that, it is also important to note that chronic kidney disease (CKD) often occurs per se, so that patients may suffer CKD as an add-on to, rather than a complication of T2DM. Nevertheless, by accounting for approximately 50% of cases, DKD is one of the most frequent complications of T2DM, leading to end-stage renal disease (ESRD) in developed countries. Incidence rates for DKD-related ESRD remain stable over the past few years [2,3], with high-risk subgroups clearly identified as middle-aged African Americans, Native Americans, and Hispanics, likely due to the ever-increasing earlier-onset disease rates in these populations leading to longer and longer-duration DM complications [4].

Incidence rates for DKD-related ESRD remain stable over the past few years [2,3], with high-risk subgroups identified as middle-aged African Americans, Native Americans, and Hispanics, likely due to the ever-increasing earlier-onset disease rates these populations leading to longer and longer-duration DM complications [4]. The overall DKD-related health costs are extraordinarily high, mainly depending on the solid relationship linking DKD to cardiovascular disease (CVD) and ESRD [3]. For example, in 2011, overall expenditures for diabetes and CKD were approximately \$25 billion in the Medicare population, mostly involving over65s, whose yearly costs per person were \$20,000 at the transition to ESRD compared to the \$40,000 calculated for patients <65 years of age. According to a positive and negative function, albuminuria and glomerular filtration rate (GFR) appear independently and additively associated, respectively, with all-cause and CVD mortality. The observation that most of the excess CVD prevalence in T2DM is accounted for by DKD strengthens this finding [5].

Hypoglycemic risk increases at estimated glomerular filtration rate (eGFR) levels <60 ml/min/1.7m<sup>2</sup> (i.e., in the presence of CKD), partly due to decreased kidney-related gluconeogenesis and slower glucose-lowering drug clearance rate [6,7]. Therefore, many

\* Corresponding author. Nefrocenter Research Network & Nyx Innovative Research Start-Up, Naples, Italy.

E-mail address: [tere.dellacorte@gmail.com](mailto:tere.dellacorte@gmail.com) (T. Della Corte).

<sup>1</sup> the complete list of members is available in supplementary material.

hypoglycemic agents require dose adjustments in people with DKD. Moreover, insulin clearance rate decreases parallel to eGFR [6–8], so that even more frequent self-monitoring of blood glucose (SMBG) than usual and accurate individualized dose titration are critical to achieving treatment goals while also avoiding hypoglycemia (Hypo) [6–8], which older individuals are per se at greater risk for [9,10]. Clinicians should also pay special attention to the fact that patients on long-term dialysis experience malnutrition, which, in turn, often asks for less exogenous insulin [6]. All the above explains why current guidelines suggest less stringent HbA1c treatment targets in older patients with DKD [11].

Due to the markedly reduced eGFR observed in renal failure, only a few DM-related medications are recommended in patients on dialysis, including insulin which, however, being burdened by a high Hypo risk, requires a substantial dose reduction over time [12–14]. Indeed, despite mostly asymptomatic, Hypos occur pretty often in dialyzed people as a result of factors different from glucose-lowering agents, including dietary errors, prolonged fasting, alcohol intake, chronic malnutrition, malignancies, heart/liver/kidney failure, adrenal or thyroid hormone deficiency, beta-blockers or other drugs.

Hypo risk increases in patients with advanced DKD transitioning to dialysis. The rate of severe Hypos requiring hospitalization further increases soon after that, by displaying a solid association with one-year mortality [15], mainly because, as well known to nephrologists, a marked intra- and between-day glycemic variability (GV) occurs, which further increases CVD risk resulting from intermittently enhanced insulin clearance rate [14,16–20]. In greater detail, Hypo risk progressively increases during the critical dialysis transition period, being more strongly associated with stroke, insulin utilization, and hemodialysis (rather than peritoneal dialysis) [15].

GV, i.e., the occurrence of several episodes of hyper- and hypoglycemia within a relatively short period, is a challenge for all insulin-treated patients, especially those with ESRD or on chronic hemodialysis. Besides focusing on insulin type and the amount needed to compensate glucose intake when reviewing their patients' glucose logs or meter downloads, clinicians should consider adherence to the appropriate insulin injection technique (IT) as, at least, equally relevant to attain optimal metabolic control.

Although being very well known due to carefully controlled studies led on healthy resting subjects, insulin pharmacokinetics (PK) is influenced by many factors, including whether the hormone gets into the subcutaneous (SC) fat or the muscle.

The SC route is used for insulin delivery because expected to ensure much more consistent hormonal absorption rates than intramuscular injections (IMIs). Nevertheless, being longer than needed, many needles commonly used with insulin pens and syringes increase the risk for IMIs, which may markedly and unpredictably increase insulin uptake, indeed, both per se and depending on whether the muscle is at rest or exercised [21]. Patients are often taught to lift skinfolds or at least to angle needles by 45° to the skin to minimize such risk. However, the best solution consists of simply promoting the utilization of short needles.

Moreover, improper IT entails an even more worrying consequence, i.e., skin lipohypertrophy (LH), which, indeed, LH affects several insulin-treated patients [22–26] (Figs. 1–3). Poor injection site rotation and frequent needle reuse are the most common factors associated with LH, as injecting into LH can reduce insulin absorption and expected activity, thus allowing postprandial glucose to increase sharply and causing highly variable insulin uptake [26]. Despite this, health care professionals (HCPs) do not perform injection site inspections routinely, hence the “unexplained” nature of many blood glucose fluctuations. Approximately half a billion people have diabetes [27]. Insulin users are estimated



Fig. 1. Easily seen proximal forearm (an abnormal injection site) LH lesion.

to be 150–200 million worldwide [28], including all people with type 1 diabetes and around 20–25% of those with T2DM, primarily through repeated daily injections. Despite being the most effective glucose-lowering medication for diabetes, insulin has one of the lowest therapeutic indexes among medications and is endowed with a high Hypo risk, according to the Institute for Safe Medications Practices [29]. Improper IT can further increase such a risk.

LH is the most frequent local complication of both insulin injections [22–26,30] and pump-related infusions [31,32], with some 50% prevalence rates according to different studies from various countries [30]. As altered PK due to delayed or erratic absorption from LH adversely affects insulin action (i.e., pharmacodynamics, PD), and, therefore, glycemic control [33–36], HCPs taking care of insulin-treated patients should make it a habit to check for LH frequently (at least yearly), especially when facing high GV or unexplained Hypos.

A recent crossover glucose clamp study showed dramatic insulin PK and PD changes after injections into LH areas, with a 3- to 5-fold more significant variability than healthy skin. A controlled mixed-meal tolerance test in the same study showed prolonged hyperglycemia after injection into LH lesions, as well [26]. Also, patients with LH require significantly higher daily insulin doses than those without LH [22,24], which leads to substantially increased direct costs for patients or payers. When patients stop injecting insulin into LH lesions and start using healthy tissue, Hypo risk and GV, daily insulin requirement, and related costs consistently decrease [22,25,37]. The key message, in the end, is that insulin injections should never get into LH areas.

In a recent multicenter observational study focusing upon LH identification at injection sites in an extensive series of dialyzed diabetic subjects, for the first time to our knowledge, we found that over 50% of ESRD/dialyzed patients suffer LH due to inappropriate IT, including missing injection site rotation, long-needle utilization and too small skin areas chosen for injections [38]. The damage caused to hemodialyzed insulin-treated patients by LH-dependent increase in GV and Hypo prevalence rates is more relevant than expected from periodic dialysis on/off switch. Therefore, education to the appropriate IT would markedly decrease GV, Hypo risk, and diabetes costs in such a clinical set, too [22,23,25].

In conclusion, as great GV and frequent symptomatic/severe Hypos are independent risk factors for CV-related and all-cause mortality, as well as hospitalization [39–43], we firmly believe that future investigations concerning Hypo risk in patients on dialysis should always take into account the outstanding contribution to that risk provided by LH lesions. Moreover, all HCPs involved in dialysis units should be aware of best practices to prevent LH development and progression [44] to set patients free



Fig. 2. Easily seen proximal forearm (an abnormal injection site) LH lesion.



Fig. 3. Easily seen proximal forearm (an abnormal injection site) LH lesion.

from the associated metabolic burden bound to disrupt further their ESRD-related intrinsically poor quality of life.

### Funding

The paper was supported by a non-conditioning special grant of NYX Start-Up, Naples, Italy.

### Authorship

All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published: Sandro Gentile, Giuseppina Guarino, Teresa Della Corte, Ersilia Satta, Carmine Romano e Carmelo Alfarone, and Felice Strollo.

### Authorship contributions

SG and FS created the paper and wrote it. GG, ES, TDC, CA, CR, critically read and approved the paper. All approved the final text. All Collaborators critically read and approved the final text.

### Compliance with ethics guidelines

This study was conducted in conformance with good clinical practice standards. The study was led in accordance with the original Declaration of Helsinki and its later amendments, and was approved by Vanvitelli University, Naples, Italy. Written informed consent was obtained from all patients before publishing their photos.

### Open access

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

### Compliance with ethics guidelines

This article is based on previous conducted studies and does not contain any studies with human participants or animals performed by any of the authors.

### Declaration of competing interest

None of the authors has conflicts of interest to declare.

### Acknowledgements

Special thanks are due to Paola Murano and to Members of Nefrocenter Research & Nyx Start-Up Study Group, for editorial assistance. The complete member list of Collaborators and Researchers is available in the Supplementary Material. A sincere thanks is due to the patients portrayed in the images, who authorized their publication.

### Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.dsx.2021.05.018>.

### References

- [1] de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. *J Am Med Assoc* 2011 Jun 22;305(24):2532–9. <https://doi.org/10.1001/jama.2011.861>.
- [2] Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US renal data system 2013 annual data report. *Am J Kidney Dis* 2014;63(1 Suppl): e219–20.
- [3] Collins AJ, Foley RN, Chavers B, Gilbertson D, Herzog C, Ishani A, et al. US renal data system 2013 annual data report. *Am J Kidney Dis* 2014;63(1 Suppl): e212–6.
- [4] Tuttle KR, Bakris GL, Bilous RW, Chiang JL, de Boer IH, Goldstein-Fuchs J, et al. Diabetic kidney disease: a report from an ADA Consensus Conference. *Am J Kidney Dis* 2014 Oct;64(4):510–33. <https://doi.org/10.1053/j.ajkd.2014.08.001>.
- [5] Gerich JE, Meyer C, Woerle HJ, Stumvoll M. Renal gluconeogenesis: its importance in human glucose homeostasis. *Diabetes Care* 2001 Feb;24(2): 382–91.
- [6] National Kidney Foundation. KDOQI clinical practice guideline for diabetes and CKD: 2012 update. *Am J Kidney Dis* 2012;60:850–86.
- [7] Mühlhauser I, Toth G, Sawicki PT, Berger M. Severe hypoglycemia in type 1 diabetic patients with impaired kidney function. *Diabetes Care* 1991;14: 344–6.
- [8] Sheen AJ. Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease. *Expert Opin Drug Metabol Toxicol* 2013;9: 529–50.
- [9] Zammitt NN, Frier MB. Hypoglycemia in type 2 diabetes: pathophysiology,

- frequency, and effects of different treatment modalities. *Diabetes Care* 2008;28:2948–61.
- [10] Whitner RA, Karter AJ, Yaffe K, Quesenberry Jr CK, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. *J Am Med Assoc* 2009;301:1565–72.
- [11] Ismail-Beigi F, Moghissi F, Tikin M, Hirsh IB, Inzucchi SE, Genuit S. Individualizing glycemic target in type 2 diabetes mellitus: implication of recent clinical trials. *Ann Intern Med* 2011;154:554–9.
- [12] Arnouts P, Bolignano D, Nistor I. Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. *Nephrol Dial Transplant* 2014;29(7):1284–300.
- [13] Guideline development group. Clinical practice guideline on management of patients with diabetes and chronic kidney disease stage 3b or higher (eGFR<45ml/min). *Nwephrol Dial Transplant* 2015;30:1–142.
- [14] Xia J, Yin C. Glucose variability and coronary artery disease. *Heart Lung Circ* 2019 Apr;28(4):553–9. <https://doi.org/10.1016/j.hlc.2018.10.019>. Epub 2018 Nov 12.
- [15] Hsiao CC, Tu HT, Lin CH, Chen KH, Yeh YH, See LC. Temporal trends of severe hypoglycemia and subsequent mortality in patients with advanced diabetic kidney diseases transitioning to dialysis. *J Clin Med* 2019 Mar 27;8(4):E420. <https://doi.org/10.3390/jcm8040420>. pii.
- [16] Ceriello A, Monnier L, Owens D. Glycaemic variability in diabetes: clinical and therapeutic implications. *Lancet Diabetes Endocrinol* 2019 Mar;7(3):221–30. [https://doi.org/10.1016/S2213-8587\(18\)30136-0](https://doi.org/10.1016/S2213-8587(18)30136-0). Epub 2018 Aug 13.
- [17] Zhou JJ, Schwenke DC, Bahn G, Reaven P, Investigators VADT. Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial. *Diabetes Care* 2018 Oct;41(10):2187–94. <https://doi.org/10.2337/dc18-0548>. Epub 2018 Aug 6.
- [18] Lo SC, Kornelius E, Huang JY, Lai YR, Huang CN, Yang YS, Chiou JY. Early cardiovascular risk and all-cause mortality following an incident of severe hypoglycaemia: a Population-based Cohort Study. *Diabetes Obes Metabol* 2019 Apr 11. <https://doi.org/10.1111/dom.13746> [Epub ahead of print].
- [19] International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. *Lancet Diabetes Endocrinol* 2019 Mar 26;S2213–8587(18). [https://doi.org/10.1016/S2213-8587\(18\)30315-2](https://doi.org/10.1016/S2213-8587(18)30315-2). 30315-2.
- [20] Park HK. Severe hypoglycemia and cardiovascular disease in type 2 diabetes. *Diabetes Metab J* 2015;39:478–80. <https://doi.org/10.4093/dmj.2015.39.6.478>.
- [21] Vaag A, Handberg A, Lauritzen M, Henriksen JE, Pedersen KD, Beck-Nielsen H. Variation in absorption of NPH insulin due to intramuscular injection. *Diabetes Care* 1990 Jan;13(1):74–6.
- [22] Blanco M, Hernandez MT, Strauss KW, Amaya M. Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes. *Diabetes Metab* 2013;39:445–53.
- [23] Gentile S, Strollo F, Ceriello A. Lipodystrophy and associated risk factors in insulin-treated people with diabetes. *Int J Endocrinol Metabol* 2016 Apr;14(2). <https://doi.org/10.5812/ijem.33997>. Published online 2016 Apr 26, <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035773/>.
- [24] Ji L, Sun Z, Li Q, Qin G, Wei Z, Liu J, Chandran AB, Hirsch LJ. Lipohypertrophy in China: prevalence, risk factors, insulin consumption, and clinical impact. *Diabetes Technol Therapeut* 2017 Jan;19(1):61–7. <https://doi.org/10.1089/dia.2016.0334>.
- [25] Grassi G, Scuterio P, Trepiccioni R, Marrubi F, Strauss KW. Optimizing insulin injection technique and its effects on blood glucose control. *J Clin Translational Endocrinol* 2014;1(4):145–50.
- [26] Famulla S, Hövelmann U, Fischer A, Coester HV, Hermanski L, Kalthheuer M, et al. Insulin injection into lipohypertrophic tissue: blunted and more variable insulin absorption and action and impaired postprandial glucose control. *Diabetes Care* 2016;39:1486e92.
- [27] Centers for Disease Control and Prevention. Age-adjusted percentage of adults with diabetes using diabetes medications, by type of medications. United States. 1997–2011. Available from, [www.ede.gov/diabetes/statistics/fig.2.htm](http://www.ede.gov/diabetes/statistics/fig.2.htm). [Accessed 1 December 2019].
- [28] Garg SK, Rewers AH, Akturk HK. Ever-increasing insulin-requiring patients globally. *Diabetes Technol Therapeut* 2018;20(Suppl.2):S21–4.
- [29] Institute for Safe Medications Practices. Insulin, Opioids warrant vigilance as high harm drugs. Available from, [www.ismp.org/news/insulin-opioids-warrant-vigilance](http://www.ismp.org/news/insulin-opioids-warrant-vigilance). [Accessed 1 December 2019].
- [30] Deng N, Zhang X, Zhao F, Wang Y, He H. Prevalence of lipohypertrophy in insulin-treated diabetes patients. A systematic review and meta-analysis. *J Diabetes Investig* 2017;9:536–43.
- [31] Conwell LS, Pope E, Artiles AM, Mohanta A, Daneman A, Daneman D. Dermatological complications of continuous subcutaneous insulin infusion in children and adolescents. *J Pediatr* 2008 May;152(5):622–8. <https://doi.org/10.1016/j.jpeds.2007.10.006>. Epub 2008 Jan 22.
- [32] Pickup JC, Yemane N, Brackenridge A, Pender S. Nonmetabolic complications of continuous subcutaneous insulin infusion: a patient survey. *Diabetes Technol Therapeut* 2014 Mar;16(3):145–9. <https://doi.org/10.1089/dia.2013.0192>. Epub 2013 Nov 1.
- [33] Gentile S, Agrusta M, Guarino G, et al. Metabolic consequences of incorrect insulin administration techniques in aging subjects with diabetes. *Acta Diabetol* 2011;48(2):121–5.
- [34] Young RJ, Hannan WJ, Frier BM, et al. Diabetic lipohypertrophy delays insulin absorption. *Diabetes Care* 1984;7(5):479–80.
- [35] Johansson U, Amsberg S, Hannerz L, et al. Impaired absorption of insulin aspart from lipohypertrophic injection sites. *Diabetes Care* 2005;28(8):2025–7.
- [36] Chowdhury TA, Escudier V. Poor glycemic control caused by insulin induced lipohypertrophy. *BMJ* 2003;327(7411):383–4.
- [37] Gentile S, Strollo F, Nefrocenter Research Study Group. Cost saving effects of a short-term educational intervention entailing lower hypoglycaemic event rates in people with type 1 diabetes and lipo-hypertrophy. *Diabetes Res Clin Pract* 2018 Sep;143:320–1. <https://doi.org/10.1016/j.diabres.2018.07.030>. Epub 2018 Aug 1.
- [38] Gentile S, Strollo F, Satta E, Della Corte T, Romano C, Guarino G, , Nefrocenter Research Study Group: Nephrologists, Diabetologists Nurses. Insulin-related lipohypertrophy in hemodialyzed diabetic people: a multicenter observational study and a methodological approach. *Diabetes Ther* 2019 Aug;10(4):1423–33. <https://doi.org/10.1007/s13300-019-0650-2>. Epub 2019 Jun 20.
- [39] Giorda CB, Ozzello A, Gentile S, Corsi A, Iannarelli R. Incidence and correlates of lipohypertrophy in type 2 diabetes. The hypos-1 study. *J Diabetes Metabol* 2014;5:344. <https://doi.org/10.4172/2155-6156.1000344>.
- [40] Giorda CB, Rossi MC, Ozzello O, Gentile S, Agliarolo A, Chiambretti A, Baccetti F, Gentile FM, Romeo F, Lucisano G, Nicolucci A. On behalf of theHYPOS-1 Study Group of AMD. Healthcare resource use, direct and indirect costs of hypoglycemia in type 1 and type 2 diabetes, and nationwide projections Results of the HYPOS-1 study. *Nutr Metabol Cardiovasc Dis* 2017 Mar;27(3):209–16.
- [41] Snell-Bergeon JK, Wadwa RP. Hypoglycemia, diabetes, and cardiovascular disease. *Diabetes Technol Therapeut* 2012 Jun;14(Suppl 1). <https://doi.org/10.1089/dia.2012.0031>. S-51–S-58.
- [42] Zhou JJ, Schwenke DC, Bahn G, Reaven P, Investigators VADT. Glycemic variation and cardiovascular risk in the veterans affairs diabetes trial. *Diabetes Care* 2018 Oct;41(10):2187–94. <https://doi.org/10.2337/dc18-0548>. Epub 2018 Aug 6.
- [43] Liang S, Yin H, Wei C, Xie L, He H, Liu X. Glucose variability for cardiovascular risk factors in type 2 diabetes: a meta-analysis. *J Diabetes Metab Disord* 2017 Nov 14;16:45. <https://doi.org/10.1186/s40200-017-0323-5>.eCollection2017.
- [44] Gentile S, Guarino G, Della Corte T, et al., AMD-OSDI Study Group on Injection Technique, Nefrocenter Research and Nyx Start-Up. Role of structured education in reducing lipodystrophy and its metabolic complications in insulin-treated people with type 2 diabetes: a randomized multicenter case-control study. *Diabetes Ther* 2021 Mar 18. <https://doi.org/10.1007/s13300-021-01006-0>. 10.1007/s13300-021-01006-0. Epub ahead of print. PMID: 33738775.